Vitiligo associated with type 2 immune inhibitors: FAERS analysis and literature review
Lu Lu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorJindi Feng
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorShiyu Zhang
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorHuimin He
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorZhonghui Hu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorLu Yang
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorCorresponding Author
Yuehua Liu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Correspondence
Yuehua Liu and Tao Wang, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing 100730, China.
Email: [email protected] and [email protected]
Bin Zhao, Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Bin Zhao
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, SAR, China
Correspondence
Yuehua Liu and Tao Wang, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing 100730, China.
Email: [email protected] and [email protected]
Bin Zhao, Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Tao Wang
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Correspondence
Yuehua Liu and Tao Wang, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing 100730, China.
Email: [email protected] and [email protected]
Bin Zhao, Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Email: [email protected]
Search for more papers by this authorLu Lu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorJindi Feng
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorShiyu Zhang
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorHuimin He
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorZhonghui Hu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorLu Yang
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Search for more papers by this authorCorresponding Author
Yuehua Liu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Correspondence
Yuehua Liu and Tao Wang, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing 100730, China.
Email: [email protected] and [email protected]
Bin Zhao, Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Bin Zhao
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, SAR, China
Correspondence
Yuehua Liu and Tao Wang, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing 100730, China.
Email: [email protected] and [email protected]
Bin Zhao, Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Tao Wang
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China
Correspondence
Yuehua Liu and Tao Wang, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing 100730, China.
Email: [email protected] and [email protected]
Bin Zhao, Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Email: [email protected]
Search for more papers by this authorLu Lu, Jindi Feng, and Shiyu Zhang are co-first authors of this paper.
Abstract
With the widespread use of type 2 immune response inhibitors (IRIs), there is growing concern about their association with the occurrence of vitiligo. This study aimed to comprehensively search for cases of vitiligo associated with type 2 IRIs in the US Food and Drug Administration Adverse Event Reporting System (FAERS). We retrieved the clinical characteristics of cases from January 2004 to September 2024 from the FAERS database. Disproportionality and Bayesian analyses were conducted to detect signals for vitiligo associated with type 2 IRIs. A total of 86 cases of vitiligo were identified in association with these inhibitors. The mean onset time was 326 days. Vitiligo associated with dupilumab was the most common (81.4%), with the highest reporting odds ratio (2.67, 95% confidence interval 2.11–3.4), proportional reporting ratio (2.67, χ2 = 70.59), information component (1.38, [IC025 = 1.09), and empirical Bayes geometric mean (2.61, EBGM05 = 2.14). The link between vitiligo and type 2 IRIs underscores the need for continued pharmacovigilance to better understand these drugs and the incidence of related conditions.
CONFLICT OF INTEREST STATEMENT
None declared.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7: 145–173.
- 2Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6: 1133–1141.
- 3Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view. Sci Immunol. 2018; 3:eaat1604.
- 4Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020; 396: 345–360.
- 5Spritz RA, Santorico SA. The genetic basis of vitiligo. J Invest Dermatol. 2021; 141: 265–273.
- 6Chen J, Li S, Li C. Mechanisms of melanocyte death in vitiligo. Med Res Rev. 2021; 41: 1138–1166.
- 7Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021; 22: 757–774.
- 8Hu Z, Wang T. Beyond skin white spots: vitiligo and associated comorbidities. Front Med Lausanne. 2023; 10:1072837.
- 9Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020; 236: 571–592.
- 10Martins C, Migayron L, Drullion C, Jacquemin C, Lucchese F, Rambert J, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. J Investig Dermatol. 2022; 142: 1194–1205.
- 11Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020; 38: 621–648.
- 12Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, et al. Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol. 2017; 137: 350–358.
- 13Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013; 10: 796–803.
- 14Shao X, Chen T, Pan X, Chen S, Chen Y, Chen J. Biologic drugs induced vitiligo: case reports and review of literature. Front Immunol. 2024; 15:1455050.
- 15Ren H, Akabane AL, Kelleher K, Halverstam C, Hicks M, Schachter JR, et al. Vitiligo induced by dupilumab treatment: a case series. J Eur Acad Dermatol Venereol. 2023; 37: 2259–2261.
- 16Picone V, Napolitano M, Torta G, Fabbrocini G, Patruno C. Vitiligo during dupilumab therapy. JAAD Case Rep. 2023; 36: 51–53.
- 17Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study. J Dermatol. 2023; 50: 880–887.
- 18Takeoka S, Kamata M, Yokoi I, Takehara A, Tada Y. Rapid enlargement of vitiligo vulgaris after initiation of Dupilumab for atopic dermatitis: a case report. Acta Derm Venereol. 2021; 101:adv00581.
- 19Bazzacco G, Chersi F, Zelin E, Mazzoletti V, Di Meo N, Zalaudek I, et al. New onset vitiligo induced by dupilumab therapy for severe asthma: a case report and a short review of the literature. Ital J Dermatol Venereol. 2024; 160: 71–72.
- 20Johnson MC, Bowers NL, Strowd LC. Concurrent atopic dermatitis and psoriasis vulgaris: implications for targeted biologic therapy. Cutis. 2022; 109: 110–112.
- 21Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018; 4: 708–710.
- 22Su Z, Zeng YP. Dupilumab-associated psoriasis and Psoriasiform manifestations: a scoping review. Dermatology. 2023; 239: 646–657.
- 23Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo CD4+ T cell differentiation and function: revisiting the Th1/Th2 paradigm. Annu Rev Immunol. 2020; 38: 705–725.
- 24Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003; 21: 713–758.
- 25Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3: 133–146.
- 26Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci U S A. 1999; 96: 10800–10805.
- 27Heller NM, Matsukura S, Georas SN, Boothby MR, Rothman PB, Stellato C, et al. Interferon-gamma inhibits STAT6 signal transduction and gene expression in human airway epithelial cells. Am J Respir Cell Mol Biol. 2004; 31: 573–582.
- 28Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science. 2019; 365:eaaw6433.
- 29Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006; 16: 3–10.
- 30Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015; 75: 14–24.
- 31Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021; 22:10922.
- 32Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, et al. Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020; 34:101388.
